Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression

Transplantation

Volumn 83, Issue 6, 2007, Pages 722-726

  Kandaswamy, Raja ^a   Humar, Abhinav ^a   Casingal, Vincent ^a   Gillingham, Kristen J ^a   Ibrahim, Hassan ^a   Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cyclosporine; Immunosuppression; Kidney transplants

Indexed keywords

ANTIBODY; CALCINEURIN INHIBITOR; CYCLOSPORIN;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN INDUCTION; SURVIVAL RATE;

ADULT; CALCINEURIN; CREATININE; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; LONGITUDINAL STUDIES; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34147155347     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000256179.14038.e2     Document Type: Article

References (28)

1. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311(11): 699.
2. Sibley RK, Rynasiewicz J, Ferguson RM, et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery 1983; 94(2): 225.
3. Sommer BG, Innes JT, Whitehurst RM, et al. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 1985; 149(6): 756.
4. Ryffel B, Mihatsch MJ. Cyclosporine nephrotoxicity. Toxicol Pathol 1986; 14(1): 73.
5. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62(2): 704.
6. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
7. Khan NA, Ma I, Thompson CR, et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006; 17(1): 244.
8. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68(4): 1413.
9. Almond PS, Gillingham KJ, Sibley R, et al. Renal transplant function after ten years of cyclosporine. Transplantation 1991; 53: 316.
10. Matas AJ, Almond PS, Moss A, et al. Effect of cyclosporine on renal function in kidney transplant recipients: a 12-year follow-up. Clin Transplant 1995; 9: 450.
11. Moss A, Najarian JS, Sutherland DER, et al. 5,000 kidney transplants - a single-center experience. In: Cecka JM, Terasaki PI, eds. Clinical Transplant 2000. Los Angeles: UCLA Tissue Typing Laboratory, 2001; 159.
12. Johnson EM, Canafax DM, Gillingham KJ, et al. Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplant 1997; 11(6): 552.
13. Fioretto P, Sutherland DE, Najarian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69(5): 907.
14. Nankivell BJ, Borrows RJ, Fung CL, et al. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78(3): 461.
15. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78(4): 557.
16. Nankivell BJ, Borrows RJ, Fund CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78(2): 242.
17. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
18. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78(11): 1653.
19. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4(11): 1776.
20. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6(3): 514.
21. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18(1): 22.
22. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74(11): 1560.
23. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64(12): 1706.
24. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59(4): 1567.
25. Egidi MF, Cowan PA, Naseer A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35: 131S.
26. Peddi VR, Jensik S, Pescovitz M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19(1): 130.
27. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4(11): 1869.
28. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24(4): 379.